PhRMA On The “Defensive”: Sen. Breaux Notes Criticism Is Bipartisan
Executive Summary
The brand name pharmaceutical industry must recognize that it is a convenient political target for members of Congress in both parties, Sen. John Breaux (D-La.) warned the Pharmaceutical Research & Manufacturers of America during the association's annual meeting April 3 in Palm Beach, Fla
You may also be interested in...
Rx “Tax Holiday” Nears President’s Desk Following House Passage
A tax change that would allow U.S. pharmaceutical companies to pay a far lower duty to "repatriate" up to $500 mil. claimed by overseas affiliates remains en route to becoming law, despite objections raised by the Bush Administration
Rx “Tax Holiday” Nears President’s Desk Following House Passage
A tax change that would allow U.S. pharmaceutical companies to pay a far lower duty to "repatriate" up to $500 mil. claimed by overseas affiliates remains en route to becoming law, despite objections raised by the Bush Administration
Congressional feedback on PhRMA annual meeting
Rep. Donna Christensen (D-V.I.) had a "very good discussion" with PhRMA at the group's recent annual meeting, she tells an Alliance of Minority Medical Associations conference in Washington, D.C. April 19. "It was a very frank and open discussion about the need to ensure that patients got the best medication for their particular illness or disease," Christensen said. "Despite often having differences of opinion, we consider the pharmaceutical industry our partners in providing health care." Christensen participated in a panel discussion on access to medicines at PhRMA (1"The Pink Sheet" April 12, 2004, p. 12)...